Clinical Trial

Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum

Name: Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum — clinical trial record (NCT07511023)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal cancer.

Trial Details

NCT Number	NCT07511023
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: Merck Sharp & Dohme LLC
Conditions	Phase 2, Sacituzumab Tirumotecan, Refractory Metastatic, Unresectable Squamous, Cell Carcinoma of the Anus/ Rectum
Enrollment	20 participants
Start Date	2026-09-25
Primary Completion	2031-03-01 (estimated)
Study Completion	2033-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-06